SHARx Addresses Rx Continuity Amidst Customs Requirement Changes
SHARx, a supply-chain and procurement management company, is working to ensure that changes in U.S. customs procedures do not disrupt patient access to affordable prescription medications.
Changes to U.S. customs procedures could affect pathways for Americans seeking lower-cost prescription medications. SHARx, a company specializing in supply-chain and procurement management for pharmaceuticals, is advocating for measures to ensure continuity of access for patients requiring high-cost drugs.
The Executive Order 14411, which aims to strengthen customs enforcement, may lead to unforeseen consequences for certain medication import routes. SHARx expresses concern that these procedural shifts, with new regulations for international mail entry taking effect October 22, could impact individuals relying on foreign pharmacies for cost savings.
The company stated it is proactively preparing by developing alternative sourcing and import processes. SHARx aims to safeguard employers and their employees from potential disruptions in the pharmaceutical supply chain. This includes testing new entry procedures and exploring domestic sourcing options.
"We are hearing from our clients and partnering brokers that there are a lot of conflicting claims about the order. We want SHARx to be a source of reassurance and information. At the same time, we have a program ready for our clients that will insulate them from the bureaucratic roller coaster," said CEO Corey Durbin. The company emphasizes its ongoing commitment to providing reliable and cost-effective pharmaceutical solutions.